Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.

about

Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.

Item

http://www.wikidata.org/entity/Q55329890

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Characteristics of clinical tr ...... register-based Latvian study.

@en

Characteristics of clinical tr ...... register-based Latvian study.

@nl

type

Item

label

Characteristics of clinical tr ...... register-based Latvian study.

@en

Characteristics of clinical tr ...... register-based Latvian study.

@nl

prefLabel

Characteristics of clinical tr ...... register-based Latvian study.

@en

Characteristics of clinical tr ...... register-based Latvian study.

@nl

P1476

Characteristics of clinical tr ...... A register-based Latvian study

@en

P2093

Dainis Krievins

http://www.w3.org/2001/XMLSchema#string

Santa Purvina

http://www.w3.org/2001/XMLSchema#string

P2860

Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments

Effectiveness, safety and costs of orphan drugs: an evidence-based review

Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions

Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.

Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov.

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.

Rare diseases and orphan drugs: Latvian story

Orphan drug development: an economically viable strategy for biopharma R&D.

A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov.

Access to orphan drugs despite poor quality of clinical evidence.

P304

e0194494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1371/JOURNAL.PONE.0194494

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Konstantins Logviss

P577

2018-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29614103

http://www.w3.org/2001/XMLSchema#string

P932

5882124

http://www.w3.org/2001/XMLSchema#string